You are here

CDC: Two Out of Three People With Invasive Cancer Are Surviving 5 Years or More

Prostate is most common cancer site, report finds

Two out of three people diagnosed with cancer survive 5 years or more, according to a study from the Centers for Disease Control and Prevention (CDC) published March 13 in the Morbidity and Mortality Weekly Report.

The study found that the most common cancer sites continue to be cancers of the prostate (128 cases per 100,000 men), the female breast (122 cases per 100,000 women), the lung and bronchus (61 cases per 100,000 persons), and the colon and rectum (40 cases per 100,000 persons). Among these common cancer sites, the 5-year relative survival rate was 97% for prostate cancer, 88% for breast cancer, 63% for colorectal cancer, and 18% for lung cancer.

The cancer survival estimates are from CDC’s National Program of Cancer Registries. CDC scientists reviewed the most recent data on cases of invasive cancers reported during 2011. With the exception of urinary bladder cancer, invasive cancer is defined as cancer that has spread to surrounding normal tissue from where it began.

The authors noted that disparities in cancer incidences still persist, with greater rates among men than women and the highest rates among blacks. In addition, 5-year relative survival after any cancer diagnosis was slightly lower for blacks (60%) than for whites (65%).

Data by state show incidence rates for all cancer sites ranged from 374 cases per 100,000 persons in New Mexico to 509 cases per 100,000 persons in the District of Columbia.

“These data are an important reminder that a key to surviving with cancer is making sure everyone has access to care from early diagnosis to treatment,” said Lisa Richardson, MD, director of the CDC’s Division of Cancer Prevention and Control. “We know, for example, that early detection of colorectal cancer has had the largest impact on long-term survival rates.”

Sources: CDC; March 12, 2015; and MMWR; March 13, 2015.


Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs